Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

34P - Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 checkpoint blockade in small cell lung cancer


06 Mar 2023


Cocktail & Poster Display session


Evelyn Nguyen


Annals of Oncology (2023) 8 (1suppl_2): 100903-100903. 10.1016/esmoop/esmoop100903


E.M. Nguyen1, H. Taniguchi2, J. Chan1, T. Sen3, A. Chow1, C.M. Rudin1

Author affiliations

  • 1 Thoracic Oncology Service, Department Of Medicine, Memorial Sloan Kettering Cancer Center, 10021 - New York/US
  • 2 Respiratory Medicine Department, Nagaski University Hospital, 852-8501 - Nagasaki/JP
  • 3 Department Of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 10029 - New York/US


This content is available to ESMO members and event participants.

Abstract 34P


Small cell lung cancer (SCLC) is a highly aggressive tumor with early primary resistance and modest clinical response to immune checkpoint blockade (ICB). Mutations or transcriptional repression of the major histocompatibility complex class I (MHC-I) represent a key mechanism driving resistance to T cell-based therapies. Lysine-specific demethylase 1 (LSD1) regulates gene expression via demethylating lysines 4 and 9 of histone H3 and has been regarded as a promising therapeutic target in SCLC. Here we investigated the immunomodulatory functions of LSD1 in regulating MHC-I antigen presentation pathway (APP) and resistance to immunotherapy in SCLC.


To perturb LSD1 function, we employed the pharmacological inhibitor ORY-1001 and RNA interference to assess changes in MHC-I expression in SCLC cell lines by flow cytometry and western blot. We then performed RNA-seq to characterize whole transcriptomic changes in SCLC cells following LSD1 inhibition. To explore effects of targeting LSD1 on T cell cytolysis, we co-cultured SCLC presenting endogenous peptides with pre-activated primary cognate CD8+ T cells. Finally, we treated syngeneic immunocompetent mice bearing genetically engineered mouse model (GEMM)-derived tumors with ORY1001 and/or anti-PD-L1 to evaluate tumor growth and characterize intratumor immune activities.


We discovered a significant and strong negative correlation between expressions of KDM1A and MHC-I/APP genes in SCLC cell lines. We then demonstrated that targeting LSD1 restores MHC-I cell surface expression, transcriptionally activates APP-regulatory genes, and enhances the immunogenic profile of SCLC. Perturbation of LSD1 activates interferon signaling, specifically activating a transactivator of MHC-I genes, and functionally rescues MHC-I-restricted T cell recognition and cytolysis. Concurrent treatment of LSD1 inhibitor and anti-PD-L1 sensitizes refractory SCLC models to ICB via antitumor CD8 T cell activities.


Our data define LSD1 as a potent regulator of antigen presentation in the tumor and provide translational support for combinatory use of LSD1 inhibitors to enhance ICB sensitivity in SCLC and other MHC-I-deficient tumors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


T. Sen: Financial Interests, Personal, Research Grant: Jazz Therapeutics. C.M. Rudin: Financial Interests, Personal, Advisory Board: Bridge Medicines, Earli, Harpoon Therapeutics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.